- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US (February 2023) and EU (February 2024). Pediatric label expansion, if successful, would follow the BRAVE study readout, likely in 2028 or later.
- Why 4/10
- SKYCLARYS is already approved and commercializing with no pending PDUFA or pivotal readout in the next ~12 months. The Phase 3 BRAVE pediatric study completed enrollment in August 2026, but its 52-week primary endpoint means results are unlikely before late 2027. As a marketed product within Biogen's diversified portfolio, SKYCLARYS drives steady commercial growth but lacks a near-term binary catalyst.
SKYCLARYS has no upcoming PDUFA or pivotal readout in the next 12 months. The Phase 3 BRAVE pediatric study (ages 2-15) completed enrollment in August 2026, but its 52-week primary endpoint means topline results are unlikely before late 2027. Watch for quarterly sales growth trajectory and any label-expansion updates from the BRAVE study as the next potential catalysts.
Price Chart
Executive Summary
SKYCLARYS (omaveloxolone) is the first and only FDA-approved treatment for Friedreich's ataxia (FA), a rare neurodegenerative disease. Originally developed by Reata Pharmaceuticals and acquired by Biogen, it was approved by the FDA in February 2023 and by the European Commission in February 2024 for patients aged 16 and older. The drug is a key growth driver for Biogen, posting Q3 2026 revenue of $178.2 million (+34% year-over-year). With no pending regulatory decision or near-term binary catalyst, SKYCLARYS is a steady commercial-stage asset within Biogen's diversified portfolio.
How It Works
SKYCLARYS is a once-daily oral pill that activates the Nrf2 pathway, a protein the body uses to reduce oxidative stress and inflammation. In Friedreich's ataxia, cells are damaged by oxidative stress, and this drug helps protect nerve cells by boosting the body's natural defense system.
Trial Status
SKYCLARYS was approved by the FDA in February 2023 based on the Phase 2 MOXIe study (NCT02255435), a 48-week randomized, double-blind, placebo-controlled trial in 103 patients aged 16-40. The drug is now commercially available in the US and EU. Biogen is conducting the Phase 3 BRAVE study (NCT06953583) in pediatric patients aged 2-15, which completed enrollment ahead of schedule in August 2026. A Phase 1 BOLD study for pediatric dosing is also ongoing.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 BRAVE pediatric study topline results (estimated late 2027, 52 weeks after August 2026 enrollment completion)
- Quarterly sales reports as a key growth-portfolio metric for Biogen
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOGEN INC. 8-K BIIB ·Originating report